Jonathan Polikoff

13.8k total citations · 2 hit papers
70 papers, 4.7k citations indexed

About

Jonathan Polikoff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Jonathan Polikoff has authored 70 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 18 papers in Genetics. Recurrent topics in Jonathan Polikoff's work include Cancer Treatment and Pharmacology (21 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Jonathan Polikoff is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Jonathan Polikoff collaborates with scholars based in United States, Canada and Italy. Jonathan Polikoff's co-authors include Louis Fehrenbacher, David Ferry, Teresa Macarulla, Joe McKendrick, Jana Prausová, R Castan, Alexia Tellier, Vladimir Moiseyenko, Paul Ruff and Guy A. Van Hazel and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jonathan Polikoff

70 papers receiving 4.6k citations

Hit Papers

Addition of Aflibercept to Fluorouracil, Leucovorin, and ... 2009 2026 2014 2020 2012 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
    2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
  2. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    2009 966 citations Ronald P. DeMatteo, Karla V. Ballman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Polikoff United States 25 2.5k 2.0k 909 845 837 70 4.7k
Do Hoon Lim South Korea 34 1.5k 0.6× 2.8k 1.4× 465 0.5× 395 0.5× 771 0.9× 206 5.1k
J. Randolph Hecht United States 22 2.8k 1.1× 1.9k 0.9× 501 0.6× 617 0.7× 736 0.9× 78 4.2k
Dirk Laurent Germany 26 3.0k 1.2× 1.5k 0.7× 975 1.1× 804 1.0× 217 0.3× 76 4.7k
Florin Sirzén Sweden 18 3.6k 1.4× 2.6k 1.3× 505 0.6× 570 0.7× 630 0.8× 28 5.5k
Michaela Lehle Switzerland 19 4.2k 1.7× 4.1k 2.0× 812 0.9× 612 0.7× 1.2k 1.5× 40 7.5k
Vladimir Moiseyenko Russia 33 5.6k 2.2× 4.1k 2.0× 1.3k 1.4× 701 0.8× 1.1k 1.3× 142 8.1k
Min‐Hee Ryu South Korea 45 3.7k 1.5× 4.5k 2.2× 455 0.5× 762 0.9× 2.2k 2.7× 327 7.6k
Daniel V.T. Catenacci United States 37 4.1k 1.6× 2.9k 1.4× 1.2k 1.3× 1.1k 1.3× 634 0.8× 167 6.8k
Hisato Kawakami Japan 32 2.7k 1.1× 1.6k 0.8× 508 0.6× 666 0.8× 271 0.3× 179 3.8k
Allen Lee Cohn United States 38 4.7k 1.9× 2.4k 1.2× 1.3k 1.4× 1.0k 1.2× 186 0.2× 159 6.9k

Countries citing papers authored by Jonathan Polikoff

Since Specialization
Citations

This map shows the geographic impact of Jonathan Polikoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Polikoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Polikoff more than expected).

Fields of papers citing papers by Jonathan Polikoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Polikoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Polikoff. The network helps show where Jonathan Polikoff may publish in the future.

Co-authorship network of co-authors of Jonathan Polikoff

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Polikoff. A scholar is included among the top collaborators of Jonathan Polikoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Polikoff. Jonathan Polikoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geyer, Charles E., Hanna Bandos, Priya Rastogi, et al.. (2022). Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Research and Treatment. 193(3). 555–564. 4 indexed citations
2.
Ganz, Patricia A., Hanna Bandos, Charles E. Geyer, et al.. (2022). Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Research and Treatment. 192(1). 153–161. 1 indexed citations
3.
Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations
4.
Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581. 56 indexed citations
5.
Lonardi, Sara, Takayuki Yoshino, Radka Obermannová, et al.. (2016). Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Annals of Oncology. 27. iv40–iv40. 1 indexed citations
6.
Jones, Jeffrey A., Tadeusz Robak, Małgorzata Wach, et al.. (2016). Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7515–7515. 13 indexed citations
7.
8.
Armstrong, Andrew J., Michael Häggman, Walter M. Stadler, et al.. (2013). Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 19(24). 6891–6901. 46 indexed citations
9.
Siziopikou, Kalliopi P., Stewart Anderson, Melody Cobleigh, et al.. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Research and Treatment. 142(2). 415–421. 45 indexed citations
10.
Zinzani, Pier Luigi, Julie M. Vose, M. S. Czuczman, et al.. (2013). Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Annals of Oncology. 24(11). 2892–2897. 90 indexed citations
11.
Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →
12.
Haque, Reina, Syed A. Ahmed, Jiaxiao Shi, et al.. (2012). Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. Cancer Epidemiology Biomarkers & Prevention. 21(10). 1848–1855. 176 indexed citations
13.
Witzig, Thomas E., Julie M. Vose, Pier Luigi Zinzani, et al.. (2011). An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Annals of Oncology. 22(7). 1622–1627. 300 indexed citations
14.
Czuczman, Myron S., Julie M. Vose, Thomas E. Witzig, et al.. (2011). The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin. British Journal of Haematology. 154(4). 477–481. 34 indexed citations
15.
Ganz, Patricia A., Stephanie R. Land, Charles E. Geyer, et al.. (2011). Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. Journal of Clinical Oncology. 29(9). 1110–1116. 91 indexed citations
16.
Lai, Albert, Anh Tran, Phioanh L. Nghiemphu, et al.. (2010). Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology. 29(2). 142–148. 353 indexed citations
17.
Swain, Sandra M., Jong‐Hyeon Jeong, Charles E. Geyer, et al.. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. Obstetrical & Gynecological Survey. 65(11). 710–712. 10 indexed citations
18.
DeMatteo, Ronald P., Karla V. Ballman, Cristina R. Antonescu, et al.. (2009). Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. 373(9669). 1097–1104. 966 indexed citations breakdown →
19.
Jänne, Pasi A., Antoinette J. Wozniak, Chandra P. Belani, et al.. (2006). Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. Journal of Thoracic Oncology. 1(6). 506–512. 50 indexed citations
20.
Jänne, Pasi A., Antoinette J. Wozniak, Chandra P. Belani, et al.. (2005). Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program. Clinical Lung Cancer. 7(1). 40–46. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Do Hoon Lim Breakdown of academic impact, for papers by J. Randolph Hecht Breakdown of academic impact, for papers by Dirk Laurent Breakdown of academic impact, for papers by Florin Sirzén Breakdown of academic impact, for papers by Michaela Lehle Breakdown of academic impact, for papers by Vladimir Moiseyenko Breakdown of academic impact, for papers by Min‐Hee Ryu Breakdown of academic impact, for papers by Daniel V.T. Catenacci Breakdown of academic impact, for papers by Hisato Kawakami Breakdown of academic impact, for papers by Allen Lee Cohn
Rankless by CCL
2026